Developer docs
API playgroundTry for free, no card

Search company profiles

Natural Capsules

Full company profile

uuid003jaff

Namestring
Natural Capsules
Legal namestring
Natural Capsules Limited
Company typeenum
Public
Founded yearint
1993
Descriptiontext

Natural Capsules Limited is an Indian publicly listed pharmaceutical manufacturer (BSE: NATCAPSUQ) founded in 1993 and headquartered in Bangalore, operating with a workforce of 101–250 employees. The company specializes in the production of empty capsule shells — including hard gelatin capsules, hard cellulose (HPMC/hydroxypropyl methylcellulose) vegetable capsules, and enteric capsules designed to resist stomach acid and release contents in the intestines. These shells are sold as B2B inputs to downstream pharmaceutical manufacturers and nutraceutical companies who fill them with their own drug formulations or dietary supplement formulations.

The company serves two horizontal customer segments — pharmaceutical manufacturers requiring compliant, high-quality capsule shells for regulated drug products, and nutraceutical companies seeking vegan and clean-label encapsulation options. Its technology centers on conventional capsule manufacturing processes for both gelatin-based and plant-based (HPMC) shells, with a deliberate strategic positioning toward the HPMC segment, which industry context projects to capture 58% of the capsule market in 2026 on the back of vegan and clean-label demand. The company also operates a wholly-owned material unlisted subsidiary, Natural Biogenex Private Limited, into which intra-group capital is periodically infused via rights issues.

Natural Capsules generates revenue through direct B2B sales of manufactured capsule products to drug and supplement makers, with quote-based pricing and no publicly disclosed price list. For FY2026 (year ended March 2026), the company reported sales of Rs 187.20 crore, up 10.63% year-over-year, with Q4 FY2026 sales of Rs 58.45 crore up 29.98% YoY. However, the company swung to a consolidated net loss of Rs 17.07 crore in FY2026 from a Rs 0.43 crore net profit in FY2025, and EBITDA turned negative, indicating significant cost pressures or margin compression despite top-line growth. Leadership comprises Sunil Mundra as CEO & Managing Director and Surya Prakash as Chief Scientific Officer.

Short descriptiontext

Natural Capsules Limited is a Bangalore-based Indian pharmaceutical manufacturer founded in 1993 that produces empty hard gelatin, HPMC vegetable, and enteric capsule shells for B2B sale to pharmaceutical and nutraceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBangalore, India
HQ citystring
Bangalore
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
hard gelatin capsules, vegetable capsule shells, pharmaceutical encapsulation, nutraceutical capsule supply, enteric capsule manufacturing
Industry2 codes
1Unit-Dose & Compliance Packaging (Sachets, Strip Packs, Pill Organizers)
CodeIMALAIAHPrimaryYes
2Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
CodeHLAGABABPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
Product category
Pharmaceutical Capsule Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Capsule Product Sales
TypeHardware Sales
Description

Revenue generated from manufacturing and selling empty hard capsules (gelatin and HPMC-based), including enteric capsules, to pharmaceutical and nutraceutical companies. The company operates as a B2B supplier with products used by drug and supplement manufacturers.

coherentmarketinsights.com
Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Natural Capsules Limited manufactures and supplies empty hard capsule shells, including hard gelatin capsules and hard cellulose (HPMC) vegetable capsules, as well as enteric empty capsules. The company also produces pharmaceutical dosage forms in capsules. Products are sold to pharmaceutical and nutraceutical companies that fill capsules with their own drug or supplement formulations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • HPMC vegetable capsules projected to hold 58% market share in 2026, indicating strong demand for plant-based capsule products
Product overview1 text field

Natural Capsules Limited is a pharmaceutical and nutraceutical capsule manufacturer. The company operates through its subsidiary Natural Biogenex Private Limited. Based on industry context from market analyses, the company's product portfolio encompasses vegetable/hard capsules and enteric empty capsules, though no specific product names or detailed product information were available in the provided sources.

Product and service1 record
1Hard Gelatin Capsule Shells
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
TypeOthers
Description

Natural Biogenex Private Limited is a material unlisted subsidiary of Natural Capsules Limited. On July 10, 2026, the subsidiary allotted 1,11,202 equity shares of Rs 10 each for cash at par, aggregating to Rs 11,12,020, following an earlier approval for rights issue on May 27, 2026. This represents a routine internal financing transaction between the parent company and its subsidiary for capital infusion purposes.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ACG is India's largest integrated empty capsule manufacturer, producing both gelatin and HPMC capsules globally. It directly competes with Natural Capsules across the same pharmaceutical and nutraceutical customer base, with much larger scale and broader product breadth.

TypeDirect peer
Description

Capsugel, a Lonza business, is the global leader in capsule manufacturing, offering hard gelatin, HPMC (Vcaps), and specialty capsules. It is a direct peer to Natural Capsules in the same product categories and target markets, but with significantly greater scale, R&D, and global reach.

TypeBroad incumbent
Description

Catalent is a global CDMO offering oral solid dose development, manufacturing, and capsule filling services. It is a broad incumbent that competes with Natural Capsules in adjacent capsule-based drug product services rather than directly in empty capsule shell supply.

TypeEmerging player
Description

Aenova is a European pharmaceutical CDMO offering solid dosage form development and manufacturing, including capsule-based products. It is an emerging player with partial overlap, focused on contract manufacturing for finished dosage forms rather than empty capsule shells.

TypeDirect peer
Description

Qualicaps, part of Mitsubishi Chemical Group, is a global hard capsule manufacturer (gelatin and HPMC) serving pharmaceutical and health/nutraceutical customers. It competes directly with Natural Capsules in empty capsule shells, with stronger global distribution.

TypeDirect peer
Description

Healthcaps is an Indian manufacturer of empty hard gelatin and HPMC capsules serving pharmaceutical and nutraceutical customers. It is a direct domestic competitor to Natural Capsules with a similar product portfolio and customer focus.

TypeDirect peer
Description

Shandong Head is a Chinese empty hard capsule manufacturer producing gelatin and HPMC capsules at scale for global pharma and nutraceutical customers. It is a direct competitor to Natural Capsules, particularly in export markets where Chinese pricing pressure is acute.

TypeDirect peer
Description

Sunil Healthcare is an Indian manufacturer of empty hard gelatin and HPMC capsules serving pharmaceutical and nutraceutical markets. It is a direct domestic peer to Natural Capsules with overlapping product lines and customer segments in India.

TypeDirect peer
Description

Suheung is a Korean manufacturer of empty hard gelatin and HPMC capsules with global distribution. It is a direct peer to Natural Capsules, particularly competing in the HPMC vegetable capsule segment where both serve international nutraceutical customers.

TypeBroad incumbent
Description

Lonza is the parent company of Capsugel and a global CDMO/biologics manufacturer. It is a broad incumbent that overlaps with Natural Capsules in empty capsule manufacturing while also competing in adjacent pharmaceutical services such as fill-finish and oral solid dose manufacturing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Natural Capsules

Pharmaceutical Capsule Manufacturingnaturalcapsules.com

Natural Capsules Limited is a Bangalore-based Indian pharmaceutical manufacturer founded in 1993 that produces empty hard gelatin, HPMC vegetable, and enteric capsule shells for B2B sale to pharmaceutical and nutraceutical companies.

What Natural Capsules does

Natural Capsules Limited is an Indian publicly listed pharmaceutical manufacturer (BSE: NATCAPSUQ) founded in 1993 and headquartered in Bangalore, operating with a workforce of 101–250 employees. The company specializes in the production of empty capsule shells — including hard gelatin capsules, hard cellulose (HPMC/hydroxypropyl methylcellulose) vegetable capsules, and enteric capsules designed to resist stomach acid and release contents in the intestines. These shells are sold as B2B inputs to downstream pharmaceutical manufacturers and nutraceutical companies who fill them with their own drug formulations or dietary supplement formulations.

The company serves two horizontal customer segments — pharmaceutical manufacturers requiring compliant, high-quality capsule shells for regulated drug products, and nutraceutical companies seeking vegan and clean-label encapsulation options. Its technology centers on conventional capsule manufacturing processes for both gelatin-based and plant-based (HPMC) shells, with a deliberate strategic positioning toward the HPMC segment, which industry context projects to capture 58% of the capsule market in 2026 on the back of vegan and clean-label demand. The company also operates a wholly-owned material unlisted subsidiary, Natural Biogenex Private Limited, into which intra-group capital is periodically infused via rights issues.

Natural Capsules generates revenue through direct B2B sales of manufactured capsule products to drug and supplement makers, with quote-based pricing and no publicly disclosed price list. For FY2026 (year ended March 2026), the company reported sales of Rs 187.20 crore, up 10.63% year-over-year, with Q4 FY2026 sales of Rs 58.45 crore up 29.98% YoY. However, the company swung to a consolidated net loss of Rs 17.07 crore in FY2026 from a Rs 0.43 crore net profit in FY2025, and EBITDA turned negative, indicating significant cost pressures or margin compression despite top-line growth. Leadership comprises Sunil Mundra as CEO & Managing Director and Surya Prakash as Chief Scientific Officer.

Natural Capsules firmographics

Firmographics
Name
Natural Capsules
Legal name
Natural Capsules Limited
Website
https://naturalcapsules.com
Company type
Public
Founded year
1993
Operating status
Operating
Headcount range
101–250 employees
Short description
Natural Capsules Limited is a Bangalore-based Indian pharmaceutical manufacturer founded in 1993 that produces empty hard gelatin, HPMC vegetable, and enteric capsule shells for B2B sale to pharmaceutical and nutraceutical companies.
Ownership category
akta.pro rank

Natural Capsules industry classification

Industry
Product category
Pharmaceutical Capsule Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
akta.pro primary industry
Unit-Dose & Compliance Packaging (Sachets, Strip Packs, Pill Organizers) (IMALAIAH)
akta.pro secondary industry
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

  • Hard gelatin capsules
  • Vegetable capsule shells
  • Pharmaceutical encapsulation
  • Nutraceutical capsule supply
  • Enteric capsule manufacturing

Where Natural Capsules is headquartered

Location

Headquarters

HQ city
Bangalore
HQ country
India
HQ region
Asia

Markets served

Natural Capsules business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Capsule Product Sales: Revenue generated from manufacturing and selling empty hard capsules (gelatin and HPMC-based), including enteric capsules, to pharmaceutical and nutraceutical companies. The company operates as a B2B supplier with products used by drug and supplement manufacturers.

Go-to-market motion1 record

Natural Capsules product offering

Product offering

Core offering

Natural Capsules Limited manufactures and supplies empty hard capsule shells, including hard gelatin capsules and hard cellulose (HPMC) vegetable capsules, as well as enteric empty capsules. The company also produces pharmaceutical dosage forms in capsules. Products are sold to pharmaceutical and nutraceutical companies that fill capsules with their own drug or supplement formulations.

Product overview

Natural Capsules Limited is a pharmaceutical and nutraceutical capsule manufacturer. The company operates through its subsidiary Natural Biogenex Private Limited. Based on industry context from market analyses, the company's product portfolio encompasses vegetable/hard capsules and enteric empty capsules, though no specific product names or detailed product information were available in the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hard Gelatin Capsule Shells

Quantifiable outcome

  • HPMC vegetable capsules projected to hold 58% market share in 2026, indicating strong demand for plant-based capsule products

Companies that use Natural Capsules

Customer profile

Segments2 records

Ideal customer profiles2 records

Natural Capsules technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Natural Capsules partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Natural Biogenex Private LimitedOthersNatural Biogenex Private Limited is a material unlisted subsidiary of Natural Capsules Limited. On July 10, 2026, the subsidiary allotted 1,11,202 equity shares of Rs 10 each for cash at par, aggregating to Rs 11,12,020, following an earlier approval for rights issue on May 27, 2026. This represents a routine internal financing transaction between the parent company and its subsidiary for capital infusion purposes.

Scale indicators5 records

Recent moves3 records

Expansion highlights3 records

Natural Capsules competitors and assessment

Company assessment

Direct peers

  • ACG Worldwide: ACG is India's largest integrated empty capsule manufacturer, producing both gelatin and HPMC capsules globally. It directly competes with Natural Capsules across the same pharmaceutical and nutraceutical customer base, with much larger scale and broader product breadth.
  • Capsugel (Lonza): Capsugel, a Lonza business, is the global leader in capsule manufacturing, offering hard gelatin, HPMC (Vcaps), and specialty capsules. It is a direct peer to Natural Capsules in the same product categories and target markets, but with significantly greater scale, R&D, and global reach.
  • Qualicaps: Qualicaps, part of Mitsubishi Chemical Group, is a global hard capsule manufacturer (gelatin and HPMC) serving pharmaceutical and health/nutraceutical customers. It competes directly with Natural Capsules in empty capsule shells, with stronger global distribution.
  • Healthcaps India: Healthcaps is an Indian manufacturer of empty hard gelatin and HPMC capsules serving pharmaceutical and nutraceutical customers. It is a direct domestic competitor to Natural Capsules with a similar product portfolio and customer focus.
  • Shandong Head: Shandong Head is a Chinese empty hard capsule manufacturer producing gelatin and HPMC capsules at scale for global pharma and nutraceutical customers. It is a direct competitor to Natural Capsules, particularly in export markets where Chinese pricing pressure is acute.
  • Sunil Healthcare: Sunil Healthcare is an Indian manufacturer of empty hard gelatin and HPMC capsules serving pharmaceutical and nutraceutical markets. It is a direct domestic peer to Natural Capsules with overlapping product lines and customer segments in India.
  • Suheung Capsule: Suheung is a Korean manufacturer of empty hard gelatin and HPMC capsules with global distribution. It is a direct peer to Natural Capsules, particularly competing in the HPMC vegetable capsule segment where both serve international nutraceutical customers.

Broad incumbents

  • Catalent: Catalent is a global CDMO offering oral solid dose development, manufacturing, and capsule filling services. It is a broad incumbent that competes with Natural Capsules in adjacent capsule-based drug product services rather than directly in empty capsule shell supply.
  • Lonza Group: Lonza is the parent company of Capsugel and a global CDMO/biologics manufacturer. It is a broad incumbent that overlaps with Natural Capsules in empty capsule manufacturing while also competing in adjacent pharmaceutical services such as fill-finish and oral solid dose manufacturing.

Emerging players

  • Aenova Group: Aenova is a European pharmaceutical CDMO offering solid dosage form development and manufacturing, including capsule-based products. It is an emerging player with partial overlap, focused on contract manufacturing for finished dosage forms rather than empty capsule shells.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Natural Capsules social profiles

Digital presence

Natural Capsules financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Natural Capsules leadership team

Management profile

Number of profiles

Profiles2 records

Natural Capsules subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Natural Capsules funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Natural Capsules M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Natural Capsules

What does Natural Capsules do?

Natural Capsules Limited manufactures and supplies empty hard capsule shells, including hard gelatin capsules and hard cellulose (HPMC) vegetable capsules, as well as enteric empty capsules. The company also produces pharmaceutical dosage forms in capsules. Products are sold to pharmaceutical and nutraceutical companies that fill capsules with their own drug or supplement formulations.

Is Natural Capsules a public or private company?

Natural Capsules is a public company. It is classified as public and is currently operating.

When was Natural Capsules founded?

Natural Capsules was founded in 1993. It employs 101 to 250 people.

Where is Natural Capsules based?

Natural Capsules is headquartered in Bangalore, India, in the Asia region.

How does Natural Capsules make money?

One revenue line is on record: capsule Product Sales.

Who are Natural Capsules's main competitors?

Direct peers on record are ACG Worldwide, Capsugel (Lonza), Qualicaps, Healthcaps India, Shandong Head, Sunil Healthcare and Suheung Capsule. Broad incumbents are Catalent and Lonza Group. Aenova Group is listed as an emerging player.

Does Natural Capsules have an API?

No public API is recorded for Natural Capsules.

What industry is Natural Capsules in?

Natural Capsules's product category is Pharmaceutical Capsule Manufacturing. Its primary akta.pro industry code is IMALAIAH, Unit-Dose & Compliance Packaging (Sachets, Strip Packs, Pill Organizers), with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXNatural Capsules sets ₹178 price for promoter preferential issueNatural Capsules' board approved a revised issue price of ₹178 for equity shares and warrants in a preferential allotment to promoter Sunil L Mundra. The issue totals about ₹10 crore, with warrants requiring 25% upfront payment and an 18-month conversion window. Full conversion would raise Mundra's stake to 10.61%.ScanXNatural Capsules sets Sept 2 record date for EGM on preferential allotmentNatural Capsules Limited has set September 2, 2026 as the record date for an Extraordinary General Meeting scheduled for September 9 to seek shareholder approval for a ₹10 crore preferential allotment. The capital raise, directed solely at promoter Sunil Laxminarayan Mundra, involves equity shares and convertible warrants priced at ₹160 per unit to fund working capital and expansion. This announcement coincides with the resignation of Pramod Kasat as Independent Director of the company's subsidiary, Natural Biogenex Private Limited.ScanXNatural Capsules: Pramod Kasat resigns as independent director of subsidiaryNatural Capsules Limited reported the resignation of Pramod Kasat as Independent Director of its subsidiary, Natural Biogenex Private Limited, effective August 17, 2026. The departure was attributed to professional commitments and disclosed in compliance with SEBI LODR regulations. This event is distinct from the company's recent AGM proceedings where all resolutions were approved.Business StandardNatural Capsules reports consolidated net loss of Rs 3.98 crore in the June 2026 quarterNatural Capsules reported a consolidated net loss of Rs 3.98 crore for the quarter ended June 2026, narrowing from the Rs 5.58 crore loss recorded in the same period of the previous year. The company also saw its sales increase by 7.77% to Rs 48.71 crore during this quarter.ScanXNatural Capsules other income jumps 556% in Q1FY27 despite revenue fallNatural Capsules reported a 17% year-on-year revenue decline to ₹48.71 crore in Q1FY27, while finance costs surged 97% due to operational challenges and demand uncertainty. However, other income jumped 556% to ₹2.35 crore, offsetting some of the financial pressure as the company advanced its API manufacturing capabilities.ScanXNatural Capsules concludes 33rd AGM, approves board reshuffleNatural Capsules Limited concluded its 33rd Annual General Meeting on August 12, 2026, adopting FY26 financials and reappointing directors Jyoti Mundra and Laxminarayan Moondra. The meeting also approved related party transactions with Natural Biogenex and conducted remote e-voting under SEBI regulations. This follows a board agenda that included discussions on a preferential equity raise.ScanXNatural Capsules adds preferential equity raise to Aug 12 board agendaNatural Capsules Limited plans to discuss a preferential equity raise at its August 12, 2026, board meeting, alongside Q1FY26 results. The company also completed a rights issue through its subsidiary Natural Biogenex, which diluted the parent's stake to 66.78%.ScanXNatural Capsules stake in Natural Biogenex diluted by 2.18% due to rights issue opt-outNatural Capsules Limited opted out of a rights issue by its subsidiary Natural Biogenex Private Limited, resulting in a 2.18% dilution of its stake from 68.96% to 66.78%. The Board cited strategic fund allocation as the reason for avoiding further investment in the loss-making subsidiary, which reported a ₹43.30 crore loss despite a net worth of ₹81.24 crore. The dilution opens the door for new third-party investors in Natural Biogenex, potentially altering the subsidiary's ownership structure and strategic direction.ScanXNatural Capsules fixes record date for 33rd AGM on Aug 5Natural Capsules Ltd announced August 5, 2026 as the record date for its 33rd Annual General Meeting scheduled for August 12, 2026. The company filed the notification with BSE and NSE on July 17, 2026. This is a routine corporate governance action standard for listed companies.ScanXNatural Capsules subsidiary allots rights issue sharesNatural Biogenex Private Limited, a material unlisted subsidiary of Natural Capsules Limited, has allotted 1,11,202 equity shares of Rs 10 each for cash at par, aggregating to Rs 11,12,020. The share allotment was approved by the board on July 10, 2026, following an earlier approval for the rights issue on May 27, 2026. This capital infusion represents a routine internal financing transaction between the parent company and its subsidiary.